SGLT2 Inhibitors and Fournier's Gangrene Risk

Introduction to SGLT2 Inhibitors and Fournier's Gangrene

The American Diabetes Association and other guideline societies recommend SGLT2 inhibitors for patients with type 2 diabetes, despite the associated risk of Fournier's gangrene, as the cardiovascular and renal benefits generally outweigh this low absolute risk 1, 2, 3

Genital mycotic infections occur in 6% of SGLT2 inhibitor users versus 1% with placebo, with higher rates in women, indicating a significant increase in infection risk with SGLT2 inhibitor use 1, 2, 4
The risk of Fournier's gangrene is extremely low, but the consequences are catastrophic, with most genital infections being mild and easily treated, but severe cases progressing to Fournier's gangrene 1, 2

Diabetes mellitus itself is a significant risk factor for Fournier's gangrene, independent of medication use, with immunosuppression, including post-transplant patients on immunosuppressive therapy, significantly amplifying infection risk with SGLT2 inhibitors 1, 5, 6

The FDA recommends immediate assessment for pain or tenderness, erythema, swelling in the genital/perineal area, especially if accompanied by fever or malaise, and discontinuation of the SGLT2 inhibitor if Fournier's gangrene is suspected 3

The American College of Physicians and other guideline societies recommend counseling all patients on proper genital hygiene and early symptom recognition before initiating SGLT2 inhibitors, and considering alternative agents in patients with recurrent genital infections or immunosuppression 6, 3

SGLT2 inhibitors remain strongly recommended for patients with type 2 diabetes, chronic kidney disease, and eGFR ≥20 mL/min/1.73 m², due to their cardiovascular and renal benefits, which outweigh the low absolute risk of Fournier's gangrene in most patients 1, 2, 4, 3

The FDA explicitly recommends discontinuation of SGLT2 inhibitors if Fournier's gangrene is suspected, particularly when patients present with pain, tenderness, erythema, or swelling in the genital or perineal area accompanied by fever or malaise, as stated by the American College of Cardiology 7
The American Diabetes Association guidelines state that necrotizing fasciitis of the perineum (Fournier gangrene) is rare but requires prompt treatment if suspected, which includes stopping the SGLT2 inhibitor, according to Diabetes Care 8

The infection requires emergency surgical debridement, broad-spectrum antibiotics, and hemodynamic support—all of which necessitate cessation of the offending agent, as recommended by the World Journal of Emergency Surgery 9
The cardiovascular and renal benefits of SGLT2 inhibitors, while substantial in other contexts, are irrelevant during active life-threatening infection where mortality rates approach 20-50%, as noted by the World Journal of Emergency Surgery 9

Do not delay discontinuation while awaiting definitive diagnosis—if clinical suspicion is high based on perineal pain, erythema, swelling, crepitation, or systemic toxicity, stop the SGLT2 inhibitor immediately and proceed with emergency evaluation and treatment, as advised by the American College of Cardiology 7